Listen
XULTOPHY (insulin degludec/liraglutide), antidiabetic
DIABETOLOGY - New indication
Opinions on drugs -
Posted on
Jun 29 2017
Reason for request
Extension of indication
Insufficient actual benefit in the treatment of patients with type 2 diabetes not sufficiently controlled by a GLP-1 analogue + oral antidiabetics
- XULTOPHY now has Marketing Authorisation in the treatment of adults with type 2 diabetes to improve glycaemic control in combination with oral antidiabetics when these, combined with a GLP-1 analogue, do not provide adequate glycaemic control.
- The fixed combination of a basal insulin, insulin degludec and GLP-1 analogue does not make it possible to adjust insulin doses to achieve glycaemic goals.
- XULTOPHY has no role in the therapeutic strategy in this indication.
Clinical Benefit
| Insufficient |
- |
Clinical Added Value
| Not applicable |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
